AbbVie
ABBV
$191.08
Share price
-0.70%
Change (1 day)
12.61%
Change (1 year)
Categories
The biotechnology and pharmaceutical company Abbvie, spelled AbbVie, was founded in 2013 as a spin-off from Abbott Laboratories and is traded on the NYSE stock exchange in the S&P 100 index under the symbol “ABBV”.
Market capitalization of AbbVie (ABBV)
Market cap: $337.52 Billion USD
As of June 2025 AbbVie has a market cap of $337.52 Billion USD. This makes AbbVie the world's 27th most valuable company by market cap according to our data. The market capitalization, commonly called market cap, is the total market value of a publicly traded company's outstanding shares and is commonly used to measure how much a company is worth.
Market cap history of AbbVie from 2012 to 2025
End of year Market Cap
| Year | Marketcap | Change |
|---|---|---|
| 2025 | $337.52 B | 7.3% |
| 2024 | $314.56 B | 14.97% |
| 2023 | $273.60 B | -4.27% |
| 2022 | $285.80 B | 19.4% |
| 2021 | $239.37 B | 26.54% |
| 2020 | $189.17 B | 44.47% |
| 2019 | $130.94 B | -3.95% |
| 2018 | $136.33 B | -11.7% |
| 2017 | $154.39 B | 51.71% |
| 2016 | $101.76 B | 6.7% |
| 2015 | $95.37 B | -8.42% |
| 2014 | $104.14 B | 24.23% |
| 2013 | $83.82 B | 55.32% |
| 2012 | $53.97 B |
End of Day market cap according to different sources
On Jun 15th, 2025 the market cap of AbbVie was reported to be:
$337.52 Billion USD
$337.52 Billion USD
Market capitalization for similar companies or competitors
| Name | Marketcap | Market cap differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | $139.51 B | -58.66% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | $101.24 B | -70.00% | 🇺🇸 USA |
 Eli Lilly LLY | $735.56 B | 117.93% | 🇺🇸 USA |
 Amgen AMGN | $158.74 B | -52.97% | 🇺🇸 USA |
 Gilead Sciences GILD | $136.80 B | -59.47% | 🇺🇸 USA |
 Biogen BIIB | $19.14 B | -94.33% | 🇺🇸 USA |
 GlaxoSmithKline GSK | $85.15 B | -74.77% | 🇬🇧 UK |
 AstraZeneca AZN | $231.94 B | -31.28% | 🇬🇧 UK |
 Neurocrine Biosciences
NBIX | $12.31 B | -96.35% | 🇺🇸 USA |